Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Primary research

miR-182-5p affects human bladder cancer cell proliferation, migration and invasion through regulating Cofilin 1

Authors: Fei Wang, Dinglan Wu, Zhanping Xu, Jianxiang Chen, Jiye Zhang, Xiaojuan Li, Shiliang Chen, Fengrong He, Jianbing Xu, Liangju Su, Defan Luo, Shufang Zhang, Weifu Wang

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

Human bladder cancer is one of the common malignant tumors, and it mainly occurs in men. miR-182-5p, a member of miR-183 family, acts as tumor suppressor or oncogene in various kinds of tumors. In this study, we first investigate that the absence of miR-182-5p in human bladder cancer promotes tumor growth by regulating the expression of Cofilin 1, an actin modulating-protein.

Methods

Human bladder tumor tissue specimens were collected to detect the expression of miR-182-5p and Cofilin 1 by qRT-PCR. Luciferase activity assay was performed to demonstrate the regulation of Cofilin 1 mRNA 3′UTR by miR-182-5p. Then, cell experiments were performed to analysis the effect of miR-182-5p/Cofilin 1 pathway on tumor cell proliferation, migration, invasion and colony forming efficiency. Finally, xenograft tumor models were established to evaluate the role of miR-182-5p in tumorigenesis abilities in vivo.

Results

qRT-PCR and Western blotting analysis showed that Cofilin 1 expression was up-regulated in both bladder cancer tissues and cell lines compared with normal. Luciferase activity assay showed that miR-182-5p specifically targets Cofilin 1 mRNA 3′UTR and represses the expression of Cofilin 1. Also, miR-182-5p inhibited bladder tumor cell proliferation, migration, invasion and colony forming efficiency. Furthermore, xenograft tumor model assay showed that miR-182-5p plays a negative role in bladder cancer tumorigenesis abilities in vivo.

Conclusion

Present results suggest that miR-182-5p could inhibit human bladder tumor growth by repressing Cofilin 1 expression. Our findings may provide a new horizon for exploring therapeutic target of bladder cancer.
Literature
1.
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.PubMedCrossRef
2.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
3.
4.
Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 2003;113(1):25–36.PubMedCrossRef
5.
Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW, Ruohola-Baker H. Stem cell division is regulated by the microRNA pathway. Nature. 2005;435(7044):974–8.PubMedCrossRef
6.
7.
8.
Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25(46):6188–96.PubMedCrossRef
9.
Fu JH, Yang S, Nan CJ, Zhou CC, Lu DQ, Li S, et al. MiR-182 affects renal cancer cell proliferation, apoptosis, and invasion by regulating PI3 K/AKT/mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22(2):351–7.PubMed
10.
Li Y, Zhang H, Gong H, Yuan Y, Li Y, Wang C, et al. miR-182 suppresses invadopodia formation and metastasis in non-small cell lung cancer by targeting cortactin gene. J Exp Clin Cancer Res. 2018;37(1):141.PubMedPubMedCentralCrossRef
11.
Li Y, Zhang H, Li Y, Zhao C, Fan Y, Liu J, et al. MiR-182 inhibits the epithelial to mesenchymal transition and metastasis of lung cancer cells by targeting the Met gene. Mol Carcinog. 2018;57(1):125–36.PubMedCrossRef
12.
Zhang ZF, Wang YJ, Fan SH, Du SX, Li XD, Wu DM, et al. MicroRNA-182 downregulates Wnt/beta-catenin signaling, inhibits proliferation, and promotes apoptosis in human osteosarcoma cells by targeting HOXA9. Oncotarget. 2017;8(60):101345–61.PubMedPubMedCentral
13.
Kouri FM, Ritner C, Stegh AH. miRNA-182 and the regulation of the glioblastoma phenotype—toward miRNA-based precision therapeutics. Cell Cycle. 2015;14(24):3794–800.PubMedPubMedCentralCrossRef
14.
Li P, Sheng C, Huang L, Zhang H, Huang L, Cheng Z, et al. MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration. Breast Cancer Res. 2014;16(6):473.PubMedPubMedCentralCrossRef
15.
Xu X, Ayub B, Liu Z, Serna VA, Qiang W, Liu Y, et al. Anti-miR182 reduces ovarian cancer burden, invasion, and metastasis: an in vivo study in orthotopic xenografts of nude mice. Mol Cancer Ther. 2014;13(7):1729–39.PubMedPubMedCentralCrossRef
16.
Wallis CJ, Gordanpour A, Bendavid JS, Sugar L, Nam RK, Seth A. MiR-182 is associated with growth, migration and invasion in prostate cancer via suppression of FOXO1. J Cancer. 2015;6(12):1295–305.PubMedPubMedCentralCrossRef
17.
Vartiainen MK, Mustonen T, Mattila PK, Ojala PJ, Thesleff I, Partanen J, et al. The three mouse actin-depolymerizing factor/cofilins evolved to fulfill cell-type-specific requirements for actin dynamics. Mol Biol Cell. 2002;13(1):183–94.PubMedPubMedCentralCrossRef
18.
DesMarais V, Ghosh M, Eddy R, Condeelis J. Cofilin takes the lead. J Cell Sci. 2005;118(Pt 1):19–26.PubMedCrossRef
19.
Aizawa H, Sutoh K, Yahara I. Overexpression of cofilin stimulates bundling of actin filaments, membrane ruffling, and cell movement in Dictyostelium. J Cell Biol. 1996;132(3):335–44.PubMedCrossRef
20.
Wang W, Mouneimne G, Sidani M, Wyckoff J, Chen X, Makris A, et al. The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol. 2006;173(3):395–404.PubMedPubMedCentralCrossRef
21.
Tahtamouni LH, Shaw AE, Hasan MH, Yasin SR, Bamburg JR. Non-overlapping activities of ADF and cofilin-1 during the migration of metastatic breast tumor cells. BMC Cell Biol. 2013;14:45.PubMedPubMedCentralCrossRef
22.
Lu LI, Fu NI, Luo XU, Li XY, Li XP. Overexpression of cofilin 1 in prostate cancer and the corresponding clinical implications. Oncol Lett. 2015;9(6):2757–61.PubMedPubMedCentralCrossRef
23.
Liu Y, Wang Z, Huang D, Wu C, Li H, Zhang X, et al. LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling. Oncotarget. 2017;8(6):9513–24.PubMed
24.
Wang WS, Zhong HJ, Xiao DW, Huang X, Liao LD, Xie ZF, et al. The expression of CFL1 and N-WASP in esophageal squamous cell carcinoma and its correlation with clinicopathological features. Dis Esophagus. 2010;23(6):512–21.PubMedCrossRef
25.
Wang F, Wu D, He F, Fu H, Xu J, Chen J, et al. Study on the significance of Cofilin 1 overexpression in human bladder cancer. Tumori. 2017;103(6):537–42.PubMedCrossRef
26.
Wang L, Xiong L, Wu Z, Miao X, Liu Z, Li D, et al. Expression of UGP2 and CFL1 expression levels in benign and malignant pancreatic lesions and their clinicopathological significance. World J Surg Oncol. 2018;16(1):11.PubMedPubMedCentralCrossRef
27.
Wang F, Wu D, Fu H, He F, Xu C, Zhou J, et al. Cofilin 1 promotes bladder cancer and is regulated by TCF7L2. Oncotarget. 2017;8(54):92043–54.PubMedPubMedCentral
28.
Cao MQ, You AB, Zhu XD, Zhang W, Zhang YY, Zhang SZ, et al. miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol. 2018;11(1):12.PubMedPubMedCentralCrossRef
29.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.PubMedCrossRef
30.
Ghosh M, Song X, Mouneimne G, Sidani M, Lawrence DS, Condeelis JS. Cofilin promotes actin polymerization and defines the direction of cell motility. Science. 2004;304(5671):743–6.PubMedCrossRef
31.
Mouneimne G, Soon L, DesMarais V, Sidani M, Song X, Yip SC, et al. Phospholipase C and cofilin are required for carcinoma cell directionality in response to EGF stimulation. J Cell Biol. 2004;166(5):697–708.PubMedPubMedCentralCrossRef
32.
Kanellos G, Zhou J, Patel H, Ridgway RA, Huels D, Gurniak CB, et al. ADF and Cofilin1 control actin stress fibers, nuclear integrity, and cell survival. Cell Rep. 2015;13(9):1949–64.PubMedPubMedCentralCrossRef
33.
Zebda N, Bernard O, Bailly M, Welti S, Lawrence DS, Condeelis JS. Phosphorylation of ADF/cofilin abolishes EGF-induced actin nucleation at the leading edge and subsequent lamellipod extension. J Cell Biol. 2000;151(5):1119–28.PubMedPubMedCentralCrossRef
34.
Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, Coniglio S, Symons M, et al. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol. 2005;168(3):441–52.PubMedPubMedCentralCrossRef
35.
Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E, et al. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Can Res. 2004;64(23):8585–94.CrossRef
36.
Hensley PJ, Zetter D, Horbinski CM, Strup SE, Kyprianou N. Association of epithelial–mesenchymal transition and nuclear cofilin with advanced urothelial cancer. Hum Pathol. 2016;57:68–77.PubMedPubMedCentralCrossRef
37.
Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Can Res. 2006;66(15):7390–4.CrossRef
38.
Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2007;96(Suppl):R40–4.PubMed
39.
Wang M, Wang Y, Zang W, Wang H, Chu H, Li P, et al. Downregulation of microRNA-182 inhibits cell growth and invasion by targeting programmed cell death 4 in human lung adenocarcinoma cells. Tumour Biol. 2014;35(1):39–46.PubMedCrossRef
40.
Cao MQ, You AB, Zhu XD, Zhang W, Zhang YY, Zhang SZ, et al. Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol. 2018;11(1):56.PubMedPubMedCentralCrossRef
41.
Kong WQ, Bai R, Liu T, Cai CL, Liu M, Li X, et al. MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma. FEBS J. 2012;279(7):1252–60.PubMedCrossRef
Metadata
Title
miR-182-5p affects human bladder cancer cell proliferation, migration and invasion through regulating Cofilin 1
Authors
Fei Wang
Dinglan Wu
Zhanping Xu
Jianxiang Chen
Jiye Zhang
Xiaojuan Li
Shiliang Chen
Fengrong He
Jianbing Xu
Liangju Su
Defan Luo
Shufang Zhang
Weifu Wang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-0758-5

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue

Primary research

A nomogram based on 9-lncRNAs signature for improving prognostic prediction of clear cell renal cell carcinoma

Primary research

Genetic polymorphisms of estrogen receptor genes are associated with breast cancer susceptibility in Chinese women

Primary research

Development of transplantable B-cell lymphomas in the MHC-defined miniature swine model

Primary research

MKP-4 suppresses hepatocarcinogenesis by targeting ERK1/2 pathway

Primary research

Roles of β-catenin, TCF-4, and survivin in nasopharyngeal carcinoma: correlation with clinicopathological features and prognostic significance

Primary research

Epigallocatechin-3-gallate inhibits the growth and increases the apoptosis of human thyroid carcinoma cells through suppression of EGFR/RAS/RAF/MEK/ERK signaling pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits